Stock of the Day

89BIO (ETNB)

$9.67

-$0.28 (-2.8%)

Market Cap: $1.41B

About 89BIO

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.

The company was incorporated in 2018 and is headquartered in San Francisco, California.